FDA
-
-
-
-
-
-
-
Axsome starts Phase 3 trial of solriamfetol for adolescent ADHD
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
-
-
-
-
-
-
Axsome Therapeutics Recognizes Mental Health Month
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to $250 at Oppenheimer
-
-
-
-
-
-
-
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
-
-
-
-
-
-
-
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
-
-
-
-
-
-
-
Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight
-
326,104 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

